Webinar replay

Biopharma Dealmaking in 2022: Trends & Forecasts

Download the Biopharma Dealmaking eBook now

2021 was a busy year in biopharma dealmaking. There were billion-dollar deals, a flood of funding, increased early-stage partnering, and new therapeutic areas and platforms coming online. Now, armed with record amounts of cash and funding, 2022 is poised to be another remarkable year for life science companies in general and partnering specifically.

Join Chris Dokomajilar, CEO at DealForma, and Echo Zhang, Product Strategy Director at Inova, as they discuss:

  • Partnering and dealmaking trends in 2021
  • What lies ahead in 2022
Watch this replay to get expert insights from our panelists:
Chris Dokomajilar
Chris Dokomajilar
Founder & CEO
Echo Zhang
Product Strategy Director

Please complete the form below

All fields marked with a * are required.

By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.
Biopharma Dealmaking in 2022-03
Biopharma Dealmaking in 2022-08
Biopharma Dealmaking in 2022-12
Preview eBook

Download the Biopharma Dealmaking in 2022 eBook:

  • 2021 Deal Numbers: Number of Deals Across Therapeutics and Platforms.
  • Asset Types and Progress: Large Cap Biopharma Dealmaking Heading into 2022.
  • Healthcare and Life Sciences Venture: Venture Totals into Healthcare and Life Sciences by Subsector.
Download the Biopharma Dealmaking eBook now

About Inova

Inova accelerates the find, deal, and collaborate phases of biopharma partnering. Its market-leading platform is used by 60% of the world’s top 50 pharma companies to source and manage their opportunities efficiently, and its technology powers more than 50,000 partnering meetings each year at the world's most important biopharma partnering conferences, including the BIO International Convention.
With subsidiaries Labiotech and IN-PART, Inova reaches more than 100,000 readers in life sciences a month and connects a network of 6,500 industry players and academic organizations.